(Open for Symbols) Today's Screener Just Picked Up These 6 Stocks

This is a must read. If you cannot see this email properly, please click [here]( [61fa9913e01c...] --------------------------------------------------------------- [Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing]( [See How Order 14017 Could Send This Company Skyrocketing]([aff_i?offer_...] --------------------------------------------------------------- Dear Reader, We just ran our screens and wanted to point out 6 'Strong Buy' Stocks that you might want to keep an eye on....Keep in mind, these are very volatile stocks so please do your own research before you make any investments. We are not recommending these stocks. See the list below. --------------------------------------------------------------- [Copper More Critical than Lithium?]( [be7e813c-17c...](Lithium may have grabbed the headlines as a key material in building electric vehicles (EVs). But so is copper. And copper's importance in the new green economy goes far beyond EVs. Copper is critical in building wind turbines and solar panels. It's key to power lines and upgrading the national grid. Analysts say we're facing a 10-million-ton shortfall if new copper mines are not found. [See How You Can Benefit From New Copper Discoveries.](//trailer.web-view.net/Links/0X0070A73BE3F57D711AFE4AA6E76FC52D45E5E01B69C6E05068FE8440B36B3B774D9BCDABA8453F68B0AB7C7814A73417DC24D8BA8DD252F3D5204FCFBC5BDF4F58817A62CDD4649F.htm [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Geron, GERN]( - Buy to Strong Buy [TipRanks.com]( also reports that [Geron]( currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $4.33. The target pricing ranges from a high forecast of $7.00 down to a low forecast of $2.00. [Geron (GERN)](’s last closing price was $1.725 which would put the average price target at 151.01% upside. Based on 3rd party rating services including: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy Our research team shows Yahoo! Finance with a Bullish Short-Term Outlook and Barchart.com with a Strong buy rating. [Click for chart >>]( ----------------------------------------------------- [Day One Biopharmaceuticals, DAWN]( - Buy to Strong Buy [TipRanks.com]( also reports that [Day One Biopharmaceuticals]( currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $37.50. The target pricing ranges from a high forecast of $40.00 down to a low forecast of $35.00. [Day One Biopharmaceuticals (DAWN)](’s last closing price was $19.345 which would put the average price target at 93.85% upside. Based on 3rd party rating services including: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy Our research team shows Yahoo! Finance with a Bullish Short-Term Outlook and Barchart.com with a Weak buy rating. [Click for chart >>]( ----------------------------------------------------- --------------------------------------------------------------- [Biden's Plan to Confiscate Your Cash?]( [440a2c71-a6c...](On March 9, President Biden quietly signed Executive Order 14067. This Order could pave the way for Democrats holding onto power in 2024. In fact, they could control America indefinitely. A former advisor to the CIA and Pentagon believes this order could allow for legal government surveillance of all US citizens; total control over your bank accounts and purchases; and the ability to silence all dissenting voices for good. To protect your freedom and your wealth,[see his dark warning now.]( [5381a560-c43...]([aff_i?offer_...] --------------------------------------------------------------- [RxSight, RXST]( - Buy to Strong Buy [TipRanks.com]( also reports that [RxSight]( currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $19.00. The target pricing ranges from a high forecast of $24.00 down to a low forecast of $14.00. [RxSight (RXST)](’s last closing price was $14.83 which would put the average price target at 28.12% upside. Based on 3rd party rating services including: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy Our research team shows Yahoo! Finance with a Bullish Short-Term Outlook and Barchart.com with a Strong buy rating. [Click for chart >>]( ----------------------------------------------------- [Biomea Fusion, BMEA]( - Buy to Strong Buy [TipRanks.com]( also reports that [Biomea Fusion]( currently has 3 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $16.00. The target pricing ranges from a high forecast of $16.00 down to a low forecast of $16.00. [Biomea Fusion (BMEA)](’s last closing price was $11.325 which would put the average price target at 41.28% upside. Based on 3rd party rating services including: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy Our research team shows Yahoo! Finance with a Bearish Short-Term Outlook and Barchart.com with a buy rating. [Click for chart >>]( ----------------------------------------------------- --------------------------------------------------------------- [Gold explodes past $2,000, here's what's next]( [3f187473-4a8...](After what feels like nearly a decade of disappointing returns, gold is entering a major bull market. You can get started today for less than $10. [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- [Royalty Pharma, RPRX]( - Buy to Strong Buy [TipRanks.com]( also reports that [Royalty Pharma]( currently has 7 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $50.83. The target pricing ranges from a high forecast of $56.00 down to a low forecast of $47.00. [Royalty Pharma (RPRX)](’s last closing price was $42.52 which would put the average price target at 19.54% upside. Based on 3rd party rating services including: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy Our research team shows Yahoo! Finance with a Bullish Short-Term Outlook and Barchart.com with a Strong buy rating. [Click for chart >>]( ----------------------------------------------------- [Cytokinetics, CYTK]( - Buy to Strong Buy [TipRanks.com]( also reports that [Cytokinetics]( currently has 11 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $63.82. The target pricing ranges from a high forecast of $80.00 down to a low forecast of $48.00. [Cytokinetics (CYTK)](’s last closing price was $41.63 which would put the average price target at 53.30% upside. Based on 3rd party rating services including: - TipRanks.com: Strong Buy - TradingView.com: Strong Buy Our research team shows Yahoo! Finance with a Bearish Short-Term Outlook and Barchart.com with a Strong buy rating. [Click for chart >>]( ----------------------------------------------------- Pricing & Percentages as of approximately 10:00am EST. [TipRanks.com]( tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. [Get more from TipRanks.com here >>]( --------------------------------------------------------------- ["The Most Critical Metal for Global Economies"]( [e33a456c-e65...](The soaring demand for this "red rock" may be the most important development in 2022. It's key in the transition to the new green energy economies. Bloomberg News warns… "Within a decade, the world may face a massive shortfall of what's arguably the most critical metal for global economies." Copper prices have nearly doubled in the past year. [Find Out How This Is Good News for Commodity Investors.]( [5381a560-c43...]( [aff_i?offer_...] --------------------------------------------------------------- Newsletter Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Sandpiper Marketing Group, LLC | PO Box 407 | Mount Mourne | North Carolina | 28123 | United States | 8458030954 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software